It’s time to fix this mess, but first we have to understand it

Pituitary World News has undertaken an initiative to understand and share the complicated issues related to access to medications and costs so pituitary patients can join us in advocating for better healthcare systems. In that mesh of confusion, we find insurance companies, orphan drug manufacturers, specialty pharmacies, pharmacy benefit managers, also known as PBM’s, prescribers, and others that add to the costs and complicate access. The issues get even murkier when considering patients on Medicare, Medicaid, pricing models, and copay requirements.

You can help!

Our friend and contributor, Dr. Chris Yedinak, Assistant Professor of Neurological Surgery, Division of Skull Base and Cerebrovascular at the NW Pituitary Center, Oregon Health & Sciences University, Portland OR, in conjunction with an international

Tumors and adenomas: “to NET or not to NET.”

From the desk of Jorge D. Faccinetti, Pituitary World News co-founder – There seems to be a debate going on in the scientific and clinical pituitary world about what to call pituitary adenomas. The simple interpretation